title: Toxicological study of a new maintenance fluid, Veen 3G, in rats.
abstract: A study of the different volume and infusion rates of a new maintenance fluid, Veen 3G, on the general conditions of rats was investigated during the 14 days after infusion. In Experiment I, 100 ml/kg and 200 ml/kg of Veen 3G were infused at a rate of 300 ml/kg/h in male and female rats. Results were compared with those for Gurunon Ringer solution (GRS) in male and female rats. We observed only transient polyuria in animals administered by each dose of Veen 3G and GRS for 0-15 min after infusion. Necropsy was not observed in any of the animals tested 14 days after infusion. In Experiment II, 200 ml/kg of Veen 3G was infused at rates of 200, 400, 800 and 1600 ml/kg/h in male rats. At 800 and 1600 ml/kg/h, irregular respiration and decrease in movement were observed concomitantly with polyuria. Three out of 4 rats died immediately after the infusion of Veen 3G at a rate of 1600 ml/kg/h, and one rat was still alive 14 days after the infusion. In this experiment, 200 ml/kg Veen 3G was safe when we infused at a rate of less than 400 ml/kg/h in male rats. Since this rate is about 27-80 times higher than that used clinically in maintenance treatment, Veen 3G is suggested to be safe, with the exception of polyuria, in clinical situations at the standard infusion rate (5-15 ml/kg/h).
authors.affiliation: Department of Pathophysiology and Therapeutics Faculty of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Hoshi University, Tokyo, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Kamei
authors.forename: K
authors.initials: K
authors.lastname: Onodera
authors.forename: M
authors.initials: M
authors.lastname: Kawaguchi
authors.forename: M
authors.initials: M
authors.lastname: Shibata
authors.forename: M
authors.initials: M
authors.lastname: Kagawa
authors.forename: M
authors.initials: M
authors.lastname: Wachi
authors.forename: J
authors.initials: J
authors.lastname: Kojima
mesh_terms: D000818:Animals; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004573:Electrolytes / Q000008:administration & dosage / Q000633:toxicity*; D005127:Eye Color / Q000187:drug effects; D005260:Female; D005440:Fluid Therapy / Q000009:adverse effects* / Q000379:methods; D005947:Glucose / Q000008:administration & dosage / Q000633:toxicity*; D007260:Infusion Pumps / Q000009:adverse effects; D007262:Infusions, Intravenous / Q000379:methods; D007552:Isotonic Solutions / Q000008:administration & dosage / Q000633:toxicity; D008297:Male; D020714:Maximum Tolerated Dose; D011141:Polyuria / Q000139:chemically induced*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012131:Respiratory Insufficiency / Q000139:chemically induced; D000077331:Ringer's Solution; D012640:Seizures / Q000139:chemically induced
chemical_list: D004573:Electrolytes; D007552:Isotonic Solutions; D000077331:Ringer's Solution; D005947:Glucose